MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

Published:2014-06-06 Issue:10 Volume:28 Page:2104-2106
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Fernández-Rodríguez C,Bellosillo B,García-García M,Sánchez-González B,Gimeno E,Vela M C,Serrano S,Besses C,Salar A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014184.pdf

Reference15 articles.

1. Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.

2. Ngo V, Ryan M, Schmitz R, Jhavar S, Xiao W, Lim K et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115–119.

3. Jiménez C, Sebastián M, Chillón M, Giraldo P, Mariano J, Escalante F et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia 2013; 27: 1722–1728.

4. Krol ADG, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM . Primary extranodal non-Hodgkin’s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003; 14: 131–139.

5. Choi J-W, Kim Y, Lee J-H, Kim Y-S . MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 2013; 44: 1375–1381.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Good clinical response following Ibrutinib treatment of a rare case of lymphoplasmacytic lymphoma secreting IgA kappa paraprotein: A case report;Oncology Letters;2024-05-28

2. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes;Targeted Oncology;2024-04-21

3. Primary gastric diffuse large B‐cell lymphoma: A multicentre retrospective study;British Journal of Haematology;2024-04-17

4. Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma;Annals of Hematology;2023-09-02

5. Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma;European Journal of Medicinal Chemistry;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3